June date set for stent dispute:
This article was originally published in Clinica
Executive Summary
The rulings on summary judgement motions in the dispute between Boston Scientific and Cook over paclitaxel-coated stents have been set for June 6 2002. In 1997, Angiotech Pharmaceuticals granted Boston and Cook co-exclusive rights to use paclitaxel to coat coronary stents. In 2001, Cook formed a deal with Guidant allowing it to sell the coated stents. Boston filed for arbitration, alleging Cook's agreement violated the co-exclusive clause (see Clinica No 975, p 9).